Immutep Limited (IMMP)
NASDAQ: IMMP · Real-Time Price · USD
1.690
+0.040 (2.42%)
Nov 7, 2025, 4:00 PM EST - Market closed
Immutep Revenue
In the fiscal year ending June 30, 2025, Immutep had annual revenue of 5.04M AUD with 31.28% growth. Immutep had revenue of 1.90M in the half year ending June 30, 2025, with 4.17% growth.
Revenue (ttm)
5.04M AUD
Revenue Growth
+31.28%
P/S Ratio
73.52
Revenue / Employee
162,702 AUD
Employees
31
Market Cap
243.10M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 5.04M | 1.20M | 31.28% |
| Jun 30, 2024 | 3.84M | 336.16K | 9.59% |
| Jun 30, 2023 | 3.51M | -1.21M | -25.64% |
| Jun 30, 2022 | 4.71M | 851.56K | 22.04% |
| Jun 30, 2021 | 3.86M | -9.88M | -71.88% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IMMP News
- 20 days ago - Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025 - GlobeNewsWire
- 2 months ago - Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025 - GlobeNewsWire
- 3 months ago - Immutep Quarterly Activities Report Q4 FY25 - GlobeNewsWire
- 3 months ago - Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer - GlobeNewsWire
- 5 months ago - Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma - GlobeNewsWire
- 6 months ago - Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo - Benzinga
- 6 months ago - Immutep Limited: Surging On Positive Head And Neck Data - Seeking Alpha
- 7 months ago - Immutep to Participate in Upcoming Investor Conferences - GlobeNewsWire